Clinical research progress and prospect of trastuzumab deruxtecan

朱逸晖; 李　婷; 胡夕春

doi:10.19401/j.cnki.1007-3639.2021.08.009

您当前的位置：

首页 >

文章列表页 >

Clinical research progress and prospect of trastuzumab deruxtecan

更新时间：2025-12-31

- Clinical research progress and prospect of trastuzumab deruxtecan
- China Oncology Vol. 31, Issue 8, Pages: 754-761(2021)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.08.009
  CLC：
- Published Online：03 September 2021，
  
  Published：03 September 2021
- 稿件说明：
移动端阅览
朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.

朱逸晖, 李　婷, 胡夕春. Clinical research progress and prospect of trastuzumab deruxtecan[J]. China Oncology, 2021, 31(8): 754-761.
朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761. DOI： 10.19401/j.cnki.1007-3639.2021.08.009.

朱逸晖, 李　婷, 胡夕春. Clinical research progress and prospect of trastuzumab deruxtecan[J]. China Oncology, 2021, 31(8): 754-761. DOI： 10.19401/j.cnki.1007-3639.2021.08.009.

摘要

Abstract

Trastuzumab deruxtecan (DS-8201a) is a novel antibody-drug conjugate (ADC) of human epidermal growth factor receptor 2 (HER2) targeted antibody and DNA topoisomerase Ⅰ inhibitor (deruxtecan

DXd). DS-8201a has the characteristics of loading new cytotoxic drugs

high proportion of drug antibodies and high cell membrane permeability. Compared to traditional anti-HER2 drugs only aimed at patients with overexpression of HER2

DS-8201a can also play a role in tumors with high and low expressions of HER2. So far

phase Ⅰ to Ⅲ clinical trials have been carried out in a variety of solid tumors

such as breast cancer

gastric cancer

colorectal cancer and non-small cell lung cancer. Studies have shown results

including indications

toxicity and safety

determination of effective dose

comparison with existing first-line and posterior-line standard chemotherapy regimens

and efficacy comparison between monotherapy and combination therapy. It may provide a new therapeutic method for clinical treatment of tumors with overexpression or low expression of HER2

and pulmonary symptoms should be monitored during use. In this review

the drug structure characteristics

related clinical research progress and prospect of DS-8201a were summarized.

关键词

Keywords

references

Views

4648

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Current status and future perspectives of antibody-drug conjugates in breast cancer therapy

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Related Author

Jialin LIN

Wenna WANG

Binghe XU

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

Related Institution

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

AI问答

⁰